A Cross-Sectional Study on Hepatic, Renal and Endocrine Parameters in Children with Beta Thalassemia Major
Authors/Creators
- 1. Senior Resident, Department of Paediatrics, GSL Medical College, Rajahmundry.
- 2. Associate Professor, Department of Paediatrics, GSL Medical College, Rajahmundry.
- 3. Professor & Head, Department of Paediatrics, GSL Medical College, Rajahmundry.
- 4. Central Research Laboratory, GSL Medical College, Rajahmundry.
Description
Introduction: Beta-thalassemia, a common blood disorder, causes severe anemia in children with Beta-Thalassemia Major (BTM). This study at a tertiary care center in India aims to identify liver, kidney, and hormone function in children with BTM, a disease highly prevalent in this region. Methods: This hospital-based study observed children under 15 with BTM. With parental consent, researchers collected detailed medical histories, demographics, and conducted physical exams. Blood samples (3ml) were drawn for tests like liver and kidney function, blood counts, and hormone levels. Blood was stored cold for further analysis. Results: The study enrolled 38 children with BTM, with an average age of 9.4 years. There were more boys than girls (boy: girl ratio of 0.9). The study found that 40% of the children had liver involvement and 7.9% had thyroid involvement. The children also required an average of 9.8 blood transfusions per year. Conclusion: This study in children with BTM identified potential liver involvement in 40% and thyroid dysfunction in 7.9%. The high transfusion burden (9.8 annually) highlights the need for iron chelation therapy to manage complications. These findings emphasize the importance of monitoring liver, thyroid function, and iron overload for better BTM management.
Abstract (English)
Introduction: Beta-thalassemia, a common blood disorder, causes severe anemia in children with Beta-Thalassemia Major (BTM). This study at a tertiary care center in India aims to identify liver, kidney, and hormone function in children with BTM, a disease highly prevalent in this region. Methods: This hospital-based study observed children under 15 with BTM. With parental consent, researchers collected detailed medical histories, demographics, and conducted physical exams. Blood samples (3ml) were drawn for tests like liver and kidney function, blood counts, and hormone levels. Blood was stored cold for further analysis. Results: The study enrolled 38 children with BTM, with an average age of 9.4 years. There were more boys than girls (boy: girl ratio of 0.9). The study found that 40% of the children had liver involvement and 7.9% had thyroid involvement. The children also required an average of 9.8 blood transfusions per year. Conclusion: This study in children with BTM identified potential liver involvement in 40% and thyroid dysfunction in 7.9%. The high transfusion burden (9.8 annually) highlights the need for iron chelation therapy to manage complications. These findings emphasize the importance of monitoring liver, thyroid function, and iron overload for better BTM management.
Files
IJTPR,Vol14,Issue7,Article23.pdf
Files
(314.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:330527058fba1b988fffd981893e4a66
|
314.4 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-06-25
Software
References
- 1. Umar TP. Microcytic Anemia: A Brief Overview. Ann SBV 2020; 9(2): 42 – 7. 2. Ali S, Mumtaz S, Shakir HA, et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021; 9 (12): e1788. 3. Meloni A, Pistoia L, Spasiano A, et al. Oxidative Stress and Antioxidant Status in Adult Patients with Transfusion-Dependent Thalassemia: Correlation with Demographic, Laboratory, and Clinical Biomarkers. Antioxidants (Basel). 2024; 13(4): 446. 4. Sharma S, Bezboruah G. Prevalence of short stature in transfusion dependent beta thalassemia patients in a tertiary care centre in Northeast India. J Family Med Prim Care. 2022; 11(6): 2516 – 20. 5. Mohanty D, Colah RB, Gorakshakar AC et al. Prevalence of β - thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Communi ty Genet. 2013; 4(1): 33 – 42. 6. Gholizadeh L, Moudi M, Nassiri MR, et al. Frequency of β-thalassemia intermedia and major mutations in southern Iran: a singlecenter study. Hematol Transfus Med. 2014; 34 (3): 222 – 6. 7. Goudarzi H, Zakeri S, Zeinali S, et al. Clinical and hematologic characteristics of thalassemia intermedia patients: a single center experience. Int Arch Med Res. 2016; 7(1): 17 – 21. 8. Girma MA, Asrat MT, Mengistu Y, et al. Hemoglobin genotypes and clinical presentations of beta-thalassemia major patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a five-year retrospective study. BMC Res Notes. 2014; 7: 280. 9. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (NKF-KDOQI guidelines). Am J Kidney Dis. 2002; 39: S1 - S266. 10. Loannou M, Ioannou LA, Constantinou CD, et al. Full article: Beta-thalassemia: renal complications and mechanisms: a narrative review. Int J Nephrol Renov Dis. 2019; 12: 121 – 33. 11. Karakurt S, Aydin S, Aydin A, et al. Renal Function and the oxidative status among children with thalassemia major and healthy controls: a cross-sectional study. Ren Fail. 2018; 40(8): 1236 – 42. 12. Olivieri L, Brittenham GM, Maggio A, et al. Iron-chelating agents in the treatment of iron overload. N Engl J Med. 2005; 352(17): 1734 – 41. 13. Shrestha S, Joshi BD, Joshi A, et al. Clinical profile of transfusion-dependent thalassemia major children with reference to serum ferritin and liver function. Nepal J Med Sci. 2018; 6 (2): 190 – 4. 14. Brittenham GM, Nichol AD, McLaren CE, et al. Efficacy of deferasirox for the treatment of chronic iron overload in patients with betathalassemia major. N Engl J Med. 2005; 353 (13):1255 – 64. 15. Olivieri L, Brittenham GM, Maggio A, et al. Iron-chelating agents in the treatment of iron overload. N Engl J Med. 2005; 352(17): 1734 – 41. 16. Karakus N, Aydin S, Karakurt S, et al. Thyroid Function and Oxidative Status in Children With Thalassemia Major. Int J Endocrinol. 20 19; 2019: 1 – 7. 17. Karami MR, Zakeri S, Zeinali S, et al. Consanguinity and its impact on the clinical features and laboratory findings in βthalassemia intermedia patients. J Trop Med Hyg. 2016; 95 (3): 573 – 7.